Ozempic vs Mounjaro: The Two Medications and the Research Peptides Behind Them
Ozempic and Mounjaro are named together so often that many people assume they are two versions of one drug. They are not. They are two distinct prescription medicines, built on two different molecules, engineered around two different mechanisms, and produced by two different companies. This overview separates the brands from the compounds inside them, explains why a single-receptor design differs from a dual-receptor design, and then turns to the research-peptide angle that matters to laboratory buyers in Canada.
The brand names used on this page are trademarks of their makers and are cited only to identify and compare the products. Ozempic is a trademark of Novo Nordisk, and Mounjaro is a trademark of Eli Lilly. Mentioning them here does not imply any affiliation or endorsement.
| Brand | Maker | Molecule | Class | Approved use |
|---|---|---|---|---|
| Ozempic | Novo Nordisk | Semaglutide | GLP-1 receptor agonist (single incretin target) | Type 2 diabetes glycemic control |
| Mounjaro | Eli Lilly | Tirzepatide | Dual GIP and GLP-1 receptor agonist | Type 2 diabetes glycemic control |
Two brands, two molecules
Ozempic delivers semaglutide, a 31-amino-acid analogue of glucagon-like peptide-1 (GLP-1). Health Canada has approved it for glycemic control in adults with type 2 diabetes. Mounjaro delivers tirzepatide, a 39-amino-acid peptide approved for the same broad indication. The two share a family resemblance because both mimic incretin hormones, but they are engineered differently at the sequence level and at the receptor level.
Both molecules are lipidated. A fatty-acid chain is attached so the peptide binds albumin in circulation, which slows clearance and gives each a long half-life measured in days rather than minutes. That structural trick is why the branded medicines can be formulated for once-weekly administration, and it is a feature research groups examine closely when they study the peptides in the laboratory.
Mono-agonism versus dual-agonism
The core difference is how many incretin receptors each molecule engages. Semaglutide is a mono-agonist: it targets the GLP-1 receptor alone. GLP-1 signalling promotes glucose-dependent insulin release from pancreatic beta cells, blunts glucagon output, and slows gastric emptying. Because the insulin effect is glucose-dependent, GLP-1 agonism is studied as a mechanism that acts most strongly when glucose is elevated.
Tirzepatide is a dual-agonist. It engages the GLP-1 receptor and, in addition, the receptor for glucose-dependent insulinotropic polypeptide (GIP), a second incretin hormone. Adding the GIP arm is the design idea behind tirzepatide: two incretin pathways activated by a single molecule. Preclinical and mechanistic research has examined how GIP and GLP-1 signalling interact, and the dual approach is what distinguishes tirzepatide as a compound rather than a simple longer version of semaglutide. A deeper treatment of the receptor biology appears in our receptor biology overview.
The research-peptide angle
Here is where the two stories separate cleanly. The branded medicines above are finished, regulated pharmaceutical products. The underlying molecules - semaglutide and tirzepatide - are also synthesised and sold as research peptides supplied research-use-only. In that context they are laboratory reference materials, not medicines: lyophilised powder in a vial, reconstituted with bacteriostatic water for in-vitro or preclinical bench work, characterised by a certificate of analysis rather than a drug label.
A research group that wants to study GLP-1 mono-agonism at the bench can source research-grade semaglutide, while a group comparing the dual mechanism can source research-grade tirzepatide. The molecule is the same amino-acid sequence in both worlds, but the category, packaging, oversight, and permitted use are entirely different. You can review the full catalogue on the store page.
Different categories, not interchangeable
This distinction is not a technicality. A branded medicine and a research peptide are different categories and are not interchangeable. Nothing on this page suggests using research material in place of a prescribed medicine, and nothing here is a protocol for any human or veterinary purpose. Research peptides are for laboratory investigation by qualified researchers only. Anyone making a treatment decision about diabetes or weight should speak with a licensed healthcare professional, who can weigh an approved product such as Ozempic or Mounjaro against a person's full medical picture.
For side-by-side detail on how each molecule differs from its branded counterpart, see semaglutide versus Ozempic and tirzepatide versus Mounjaro. Those comparisons walk through the same axis this article introduces: same molecule, two very different categories.
The short version
Ozempic and Mounjaro are not two brands of one drug. Ozempic is semaglutide, a GLP-1 mono-agonist from Novo Nordisk. Mounjaro is tirzepatide, a dual GIP and GLP-1 agonist from Eli Lilly. Both are Health Canada approved for type 2 diabetes. Their molecules also exist as research peptides for laboratory study, and that laboratory category stands apart from the approved medicines in every practical and regulatory sense.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.